Back to Results
First PageMeta Content
AstraZeneca / MedImmune / Business / Venture capital / TRPV / Transient receptor potential channel / Pfizer / Ion channels / Membrane biology / Biology


BWTHydra Brings in 22M in Series D to Push First Program into Clinic.qxd
Add to Reading List

Document Date: 2009-01-21 17:10:08


Open Document

File Size: 77,95 KB

Share Result on Facebook

City

San Francisco / Brisbane / Palo Alto / New York / Atlanta / Cambridge / Alameda / /

Company

Singulex Inc. / Hydra Biosciences Inc. / BrainCells Inc. / J.P. Morgan / MedImmune Ventures / Anacor Pharmaceuticals Inc. / Lilly Ventures / Biogen Idec Ventures / Pfizer Inc. / Aisling Capital / Londonbased AstraZeneca plc / BiPar Sciences Inc. / AHC Media LLC / LigoCyte Inc. / AstraZeneca / Advanced Technology Ventures / /

Country

United States / Canada / /

Currency

USD / /

Event

Funding / Employment Change / /

IndustryTerm

venture capital / noncannabinoid product / platform technology / venture capital front / /

Organization

National Venture Capital Assoc. / /

Person

Russell Herndon / Karen GottingSmith / Maggie Flanagan LeFlore / /

/

Position

Jennifer Boggs Assistant Managing Editor Financial experts / president and CEO / managing director / board member / /

Product

Series D / /

ProvinceOrState

California / Georgia / Massachusetts / /

Technology

high-throughput screening / platform technology / /

URL

www.bioworld.com / /

SocialTag